Pharmacological Treatment of Bipolar Disorder: Japanese Expert Consensus 2025

Background: Clinical guidelines do not fully address complex treatment scenarios in bipolar disorder. We conducted an updated Japanese expert consensus survey using an innovative two-step design to distinguish broad acceptable therapeutic options from concrete regimen-level priorities across 17 clinical questions (CQs). Methods: Between October 3 and 17, 2025, 350 psychiatrists jointly certified in neuropsychopharmacology in Japan were surveyed. For each CQ, respondents selected all acceptable medications from a structured list (descriptively categorized as Tier 1 [≥65%], Tier 2 [35%–<65%], or Tier 3 [<35%]) and specified their single preferred regimen via free text. Results: A total of 159 psychiatrists responded (45.4%). In manic/hypomanic CQs, lithium, valproate, olanzapine, and aripiprazole frequently reached Tier 1; however, aripiprazole monotherapy was the most preferred regimen across all six CQs and the sole Tier 1 agent for perinatal mania. In acute depression, lithium, lurasidone, quetiapine extended-release, and lamotrigine predominated, whereas mixed-features and rapid-cycling CQs were characterized by valproate, lithium, olanzapine, and aripiprazole, with widely dispersed preferred regimens. In maintenance treatment, lithium, aripiprazole, and valproate predominated, with lithium most frequently preferred. Notably, candidate selections and preferred regimens diverged: lemborexant was consistently Tier 2 across all CQs but never ranked among the top three preferred regimens. Conclusions: The two-step design revealed a meaningful divergence between the breadth of clinically acceptable options and prioritized prescribing regimens. These findings deliver pragmatic, scenario-specific guidance that effectively bridges evidence-based recommendations and real-world clinical decision-making.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11673756/v1
Primary Topic
Bipolar Disorder and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pharmacological Treatment of Bipolar Disorder: Japanese Expert Consensus 2025

淳一 伊賀, Hiroyuki Muraoka, Yoshiteru Takekita, Saki Hattori et al.
1 links
Research Square
Bipolar Disorder and Treatment
preprint

Pharmacological Treatment of Bipolar Disorder: Japanese Expert Consensus 2025

淳一 伊賀, Hiroyuki Muraoka, Yoshiteru Takekita, Saki Hattori, Ken Inada, Hiromi Tagata, 靖史 川又, Hajime Baba, Akira Nishi, Hitoshi Sakurai, あすか 香月, 越智紳一郎, Kyosuke Sawada, Norio Yasui‐Furukori, Toshiaki Kikuchi, Masaki Kato, Hideaki Tani, Koichiro Watanabe
preprint en

Abstract

Background: Clinical guidelines do not fully address complex treatment scenarios in bipolar disorder. We conducted an updated Japanese expert consensus survey using an innovative two-step design to distinguish broad acceptable therapeutic options from concrete regimen-level priorities across 17 clinical questions (CQs). Methods: Between October 3 and 17, 2025, 350 psychiatrists jointly certified in neuropsychopharmacology in Japan were surveyed. For each CQ, respondents selected all acceptable medications from a structured list (descriptively categorized as Tier 1 [≥65%], Tier 2 [35%–<65%], or Tier 3 [<35%]) and specified their single preferred regimen via free text. Results: A total of 159 psychiatrists responded (45.4%). In manic/hypomanic CQs, lithium, valproate, olanzapine, and aripiprazole frequently reached Tier 1; however, aripiprazole monotherapy was the most preferred regimen across all six CQs and the sole Tier 1 agent for perinatal mania. In acute depression, lithium, lurasidone, quetiapine extended-release, and lamotrigine predominated, whereas mixed-features and rapid-cycling CQs were characterized by valproate, lithium, olanzapine, and aripiprazole, with widely dispersed preferred regimens. In maintenance treatment, lithium, aripiprazole, and valproate predominated, with lithium most frequently preferred. Notably, candidate selections and preferred regimens diverged: lemborexant was consistently Tier 2 across all CQs but never ranked among the top three preferred regimens. Conclusions: The two-step design revealed a meaningful divergence between the breadth of clinically acceptable options and prioritized prescribing regimens. These findings deliver pragmatic, scenario-specific guidance that effectively bridges evidence-based recommendations and real-world clinical decision-making.

Research Square
Kansai Medical University (JP), Toho University (JP), Kyorin University (JP), Keio University (JP), Juntendo University (JP), Ehime University (JP), Kitasato University (JP), Dokkyo Medical University (JP), Yokohama City University (JP)
Japanese Society of Clinical Neuropsychopharmacology
Good health and well-being
Bipolar Disorder and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon